The GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial was designed to prospectively study the relationship between change in natriuretic peptide concentration, cardiac remodeling, and clinical events in patients with heart failure with reduced ejection fraction (HFrEF). The trial was stopped early because biomarker-guided treatment was not more effective than usual care in improving outcomes. The GUIDE-IT Echo Substudy was a prespecified substudy designed to understand the influence of biomarker-guided therapy on cardiac structure and function.

Article by Jesse M. Ehrenfeld, MD, MPH and Jed D. Gonzalo, MD, MSc, editors of Health Systems Science Review Health Systems Science Review is the first book to help learners prepare to be assessed and faculty to develop assessments in this emerging discipline. Health systems science—the study of how health systems deliver care, how patientsMORE

Article by Marco Mula Epilepsy is one of the most frequent neurological disorders affecting around 50 million people worldwide. Over the last 30 years, the diagnosis and treatment of epilepsy has tremendously improved with new diagnostic tests, a large number of drug treatments, the development of epilepsy surgery and neurostimulation techniques. However, the incredible technicalMORE

Alcohol septal ablation was introduced as a new treatment option for symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM) about 2 decades ago, but there has been persistent concern that the alcohol-induced infarction might have adverse long-term effects and increase the risk of cardiac mortality. Batzner et al studied the long-term survival after echo-guided alcohol septal ablation (percutaneous transluminal septal myocardial ablation [PTSMA]) in symptomatic patients with HOCM.